参考文献/References:
【参考文献】 [1] 王志清,徐祖琼,朱学军.新药治疗慢性淋巴细胞白血病的进展[J].临床血液学杂志,2016,29(4):604-608. [2] Patkar N,Rabade N,Kadam P A,et al.Immunogenetics of chronic lymphocytic leukemia[J].Indian Journal of Pathology & Microbiology,2017,60(1):38-42. [3] 王彦明,钟武,周辛波.口服布鲁顿酪氨酸激酶抑制剂——ibrutinib[J].临床药物治疗杂志,2015,13(4):21-24. [4] 张怀民,傅秀慧,郑海洲.布鲁顿酪氨酸激酶抑制剂ibrutinib治疗恶性肿瘤的作用机制[J].中国医院药学杂志,2018,38 (2):209-212. [5] Itchaki G,Brown J R.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia[J]. Therapeutic Advances in Hematology,2018,9(1):3-19. [6] Hacken E T,Burger J A.Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia-focus on the B-cell receptor[J].Clinical Cancer Research,2014,20 (3):548-556. [7] Long M,Beckwith K,Do P,et al.Ibrutinib treatment improves T cell number and function in CLL patients[J].Journal of Clinical Investigation,2017,127(8):3052-3064. [8] Quinquenel A,Flore S D F,Durot E,et al.Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation[J].British Journal of Haematology,2016,176(6):997-999. [9] Primo D,Scarfo L,Xochelli A,et al.A novel,ex vivo,high- throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia [J].Oncotarget,2018,9(40):26019-26031. [10] Ten Hacken E,Guièze,Romain,Wu C J.SnapShot: Chronic Lymphocytic Leukemia[J].Cancer Cell,2017,32(5):716. [11] David W,Michael S.Chronic lymphocytic leukemia at ASH 2017[J].memo-Magazine of European Medical Oncology, 2018,11(2):105-108. [12] Burger J A,Tedeschi A,Barr P M,et al.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia -NEJM[J].The New England Journal of Medicine,2011,373 (25):2425-2437. [13] Byrd JC,Brown JR,O’Brien S,et al.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia[J].The New England Journal of Medicine,2014, 371(3):213-223. [14] Goldwirt L,Beccaria K,Ple A,et al.Ibrutinib brain distribution:a preclinical study[J].Cancer Chemotherapy Pharmacology,2018,81(4):783-789. [15] Khan K ,Malik A I,Almarzouqi S J,et al.Optic Neuropathy Due to Chronic Lymphocytic Leukemia Proven With Optic Nerve Sheath Biopsy[J].Journal of neuro-ophthalmology: the official journal of the North American Neuro- Ophthalmology Society,2016,36(1):61-66. [16] Forconi F.Five years of ibrutinib in CLL[J].Blood,2018, 131(21):2280-2281. [17] Fuerst,Mark L.Combination of ibrutinib & venetoclax shows promise in previously treated CLL[J/OL].https://journals. lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=1770. [18] Kerry A R,Ying H,Amy S,et al.Phase 1b study of obinutuzumab,ibrutinib,and venetoclax in relapsed and refractory chronic lymphocytic leukemia[J].Blood,2018,132: 1568-1572. [19] Nastoupil L,Lunning M A,Vose J M,et al.Chemo-free triplet combination of TGR-1202,ublituximab,and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL [J].Hematological ,2017,102(S2):312. [20] Gordon M J,Michael C,Hamood A,et al.Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib[J].Cancer,2018,124(15):3192-3200. - 69 - [21] Follows G A,Forum U K C.Outcomes of patients post ibrutinib treatment for relapsed/refractory CLL:A UK and Ireland analysis[J].Hematological Oncology,2017,35(S2): 237-238. [22] Chen T L,Harrington B K,Beaver L,et al.BCL3 over- expression contributes an in vivo growth advantage in a B-cell lymphoma xenograft model and is a risk factor for ibrutinib relapse in CLL[J].Cancer Research,2017,77(S13): 3014. [23] Dreger P,Michallet M,Bosman P,et al.Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma:a study by the EBMT Chronic Malignancies and Lymphoma Working Parties[J].Bone Marrow Transplantation, 2018(In Press),doi:10.1038/s41409-018-0207-4. [24] Ahn IE,Farooqui M Z H,Tian X,et al.Depth and durability of response to ibrutinib in CLL:5-year follow-up of a phase II study.[J].Blood,2018 131:2357-2366. [25] Sharma S,Galanina N,Guo A,et al.Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL[J].Oncotarget,2016,7(42):68833-68841 [26] Wang,W,Zhou,X,Li,X.Unmask the genetic backbone of ibrutinib-relapsed chronic lymphocytic leukemia progression and Richter transformation[J].Annals of Translational Medicine.2018,6(11):234. [27] Furman R R,Cheng S,Lu P,et al.Ibrutinib resistance in chronic lymphocytic leukemia[J].New England Journal of Medicine,2014,70(24):2352-2354. [28] Hamas y A,Wang Q,Blomber g KE,et al.Substitution scanning Identifies a novel,catalytically active ibrutinib-resistant BTK cysteine 481 to threonine(C481T) variant[J].Leukemia, 2017,31(1):177-185. [29] Dasanu CA.Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia[J].J Oncol Pharm Pract, 2018(In Press),doi.org/10.1177/1078155218772327. [30] Barr PM,Brown JR,Hillmen P,et al.Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated CLL.J Clin Oncol 2015;33(S15).abstract 7012.[160] Jain P,Keating M, Wierda W,et al.Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.Blood 2015;125:2062-2067. [31] Brown J R.How I treat CLL patients with ibrutinib[J]. Blood,2018,131(4):379-386. [32] Anthony R M,Suparna C,Peter P,et al.Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia[J].Cancer Biology & Therapy,2018,19(1):1-2. [33] Gianluigi R,Bruno F,Ramona C,et al.Predictors of atrial fibrillation in ibrutinib-treated CLL patients:a prospective study[J].Journal of Hematology & Oncology.2018,11(1):79. [34] Morrison V A,Rai K R,Peterson B L,et al.Impact of therapy with chlorambucil,?udarabine,or ?udarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup study cancer and leukemia group B 9011[J]. Journal of Clinical Oncology,2001,19(16): 3611-3621. [35] Kreiniz N,Bejar J,Polliack A,et al.Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma[J].Hematological Oncology,2018,36(1):349-354. [36] Stein M K,Saradasri K,Jackson R,et al.Cutaneous mucormycosis following a bullous pemphigoid flare in a chronic lymphocytic leukemia patient on ibrutinib[J].World Journal of Oncology,2018,9(2):62-65. [37] Ensi Voshtina,Huang Huiya,Renju Raj,et al.Amebic encephalitis in a patient with chronic lymphocytic leukemia on ibrutinib therapy[J].Case Reports in Hematology,2018(in press),doi/10.1155/2018/6514604. [38] Suzuki T,Miyakoshi S,Nanba A,et al.A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment[J].Journal of Clinical and Experimental Hematopathology,2018,58(3): 136-140. [39] 陈本川.治疗套细胞淋巴瘤及慢性淋巴细胞白血病新药——依鲁替尼(ibrutinib)[J].医药导报,2014,33(10):1336- 1338. [40] Morgan L.Adherence to ibrutinib therapy improves outcomes in patients with CLL[J].Am Health Drug Benefits, 2015,8(Spec Issue):39.